SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001171843-20-002185
Filing Date
2020-03-31
Accepted
2020-03-31 12:53:40
Documents
5
Effectiveness Date
2020-03-31

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a_032420.htm DEFA14A 18317
2 GRAPHIC card_1.jpg GRAPHIC 120230
3 GRAPHIC card_2.jpg GRAPHIC 193388
4 GRAPHIC card_3.jpg GRAPHIC 101783
5 GRAPHIC card_4.jpg GRAPHIC 36881
  Complete submission text file 0001171843-20-002185.txt   642650
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 20760703
SIC: 2836 Biological Products, (No Diagnostic Substances)